Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial
Published Online: 2016-04-?
Journal: The Lancet Oncology•Publisher: Elsevier BV
Authors: Angela DeMichele•Cynthia Huang Bartlett•Dennis Slamon•Hiroji Iwata•Igor Bondarenko•Jungsil Ro•Kathy Puyana Theall•Ke Zhang•Marco Colleoni•Maria Koehler•Massimo Cristofanilli•Nadia Harbeck•Nicholas C Turner•Norikazu Masuda•Seock-Ah Im•Sherene Loi•Sunil Verma•Yuqiu Jiang
